Existing standard of care in kidney transplantation provides good short-term efficacy, but there is still a need for immunosuppressive therapies that provide durable antirejection efficacy and safety while maintaining allograft unction. Currently, several targeted therapies are under development to evaluate long-term improvement in transplantation; however, there is a need for an early and robust surrogate endpoint that can adequately predict the likelihood of long-term graft survival and kidney failure prevention. Please join our symposium to understand targeted treatment pathways and innovative predictive tools for long-term allograft survival.